XTL Biopharmaceuticals shareholders approve all proposals

XTL Biopharmaceuticals Ltd. reported the outcome of its Extraordinary General Meeting of Shareholders held on June 29, 2026 in Tel Aviv.

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd. reported the outcome of its Extraordinary General Meeting of Shareholders held on June 29, 2026 in Tel Aviv. The meeting had originally been scheduled for June 22, 2026, but was adjourned by one week due to lack of quorum.

At the reconvened meeting, shareholders approved all proposals that had been described in the company’s May 15, 2026 announcement. The meeting took place at the offices of the company’s attorneys in Tel Aviv at 4:00 PM Israel time.

Key Figures

Original meeting date: June 22, 2026 Reconvened meeting date: June 29, 2026 Meeting time: 4:00 PM Israel Time +1 more

4 metrics

Original meeting date June 22, 2026 Extraordinary General Meeting initially scheduled

Reconvened meeting date June 29, 2026 Extraordinary General Meeting actually held

Meeting time 4:00 PM Israel Time Time of Extraordinary General Meeting

Adjournment length one week Delay due to lack of quorum

Key Terms

Extraordinary General Meeting of Shareholders, quorum, Form 20-F, Form 40-F, +1 more

5 terms

Extraordinary General Meeting of Shareholders financial

"it will hold Extraordinary General Meeting of Shareholders (the “Meeting”) on June 22, 2026"

A meeting called by a company outside its regular annual meeting to address urgent or special matters that cannot wait until the next scheduled meeting. Investors attend or vote to decide on actions such as major deals, leadership changes, capital-raising, or rule changes; think of it as an emergency board meeting where shareholders have a direct say and the outcomes can quickly change a company’s strategy, ownership stakes, or financial prospects.

quorum financial

"the Meeting was adjourned for one week to the same day, time and place due to lack of quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

Form 20-F regulatory

"whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

Form 40-F regulatory

"whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F"

A Form 40-F is a standardized annual filing used by certain Canadian companies that trade in U.S. markets to give U.S. regulators and investors the same core financial statements and key disclosures they file in Canada. Think of it as a translated, formally packaged annual report that lets investors in a different marketplace compare a company’s results, governance and risks more easily, which reduces uncertainty and helps investment decisions.

Report of Foreign Private Issuer regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did XTLB’s shareholders decide at the June 29, 2026 extraordinary meeting?

Shareholders of XTL Biopharmaceuticals approved all proposals presented at the June 29, 2026 Extraordinary General Meeting. These proposals were the same ones described in the company’s May 15, 2026 announcement and passed by the required shareholder majority.

Why was XTL Biopharmaceuticals’ June 22, 2026 shareholder meeting adjourned?

The Extraordinary General Meeting set for June 22, 2026 was adjourned for one week because there was no quorum. Without enough shares represented, the company could not validly vote, so the meeting reconvened on June 29, 2026 instead.

When and where did XTLB’s reconvened Extraordinary General Meeting take place?

The reconvened Extraordinary General Meeting was held on June 29, 2026 at 4:00 PM Israel time. It took place at Amit, Pollak, Matalon & Co.’s APM House offices on Raoul Wallenberg Street in the Ramat Hachayal area of Tel Aviv.

What majority was required for XTL Biopharmaceuticals’ June 29, 2026 resolutions?

Each resolution at the June 29, 2026 Extraordinary General Meeting was approved by the required shareholder majority. The company states that all proposals from its May 15, 2026 announcement received sufficient support according to the applicable voting thresholds.

Who signed the June 29, 2026 XTLB report on the shareholder meeting results?

The report on the Extraordinary General Meeting results was signed on behalf of XTL Biopharmaceuticals Ltd. by Chief Executive Officer Noam Band. His electronic signature appears with the company name and the June 29, 2026 date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:39 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of June 2026

Commission File Number: 001-36000

XTL Biopharmaceuticals Ltd. 

(Exact name of Registrant as specified in its charter)

85 Medinat ha-Yehudim St.

Herzliya,
4676670, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

On May 14, 2026, XTL Biopharmaceuticals Ltd. (the “Company”) announced that it will hold Extraordinary General Meeting of Shareholders (the “Meeting”) on June 22, 2026, at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel at 04:00 PM (Israel Time). However, on June 22, 2026, the Meeting was adjourned for one week to the same day, time and place due to lack of quorum.

The Company announces today, the results of the Meeting, held today, Monday, June 29, 2026, in Tel Aviv, Israel. At the Meeting, all of the proposals set forth in Company’s announcement dated May 15, 2026, were approved by the required majority of the shareholders. The resolutions were as follows:

1. To approve the acquisition of not less than 80% and up to 100% of the issued and outstanding share capital of Psyga Bio Ltd. (“Psyga”) as a result of which the Company shall become the controlling shareholder of Psyga, in exchange for the issuance by the Company, by way of a private placement, of the Psyga Consideration comprising of the Issued Shares and the Milestone Warrants, all as described in the proxy statement and on the terms and subject to the conditions set forth in the SPA;

2. To approve a private placement of up to US$1,500,000 from Mr. Alexander Rabinovitch (the “Interested Party”) and/or one or more other investors, to be funded conditional upon the consummation of the Transaction, as further described in the proxy statement;

3. To approve, conditional upon the approval of Resolutions 1 and 2 above, an increase of the Company’s authorized share capital by 2,900,000,000 shares, such that following the increase, the authorized share capital will consist of a total of 5,800,000,000 ordinary shares, par value NIS 0.1 each, and to amend the Company’s Articles of Association accordingly; and

4. To approve the appointment of BARZILY & CO. C.P.A (the “Auditors”), as the Company’s independent registered public accounting firm for the year ending December 31, 2025, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee, to determine the Auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XTL Biopharmaceuticals Ltd.
Date: June 29, 2026	/s/ Noam Band
	Noam Band Chief Executive Officer

2